Trophos, a biopharmaceutical company specializing in the discovery and development of novel therapeutics to treat orphan neurodegenerative diseases, announce yesterday the results from the phase 3 study of
Trophos' lead compound, olesoxime, in 512 patients with ALS. Olesoxime
did not demonstrate a significant increase in survival versus placebo in
patients receiving riluzole.
Trophos continues its ongoing research, including the ongoing pivotal trial of olesoxime in Spinal Muscular Atrophy (SMA) with results due in the second half of 2013.
Comments
Post a Comment